Mathijssen RHJ - Search Results

1

Adding metabolic agents to prostate cancer therapy: Every rose has its thorn.

Buck SAJ, Mathijssen RHJ, de Wit R. Buck SAJ, et al. Among authors: mathijssen rhj. Eur J Cancer. 2022 Jul;170:305-307. doi: 10.1016/j.ejca.2021.04.048. Epub 2022 May 11. Eur J Cancer. 2022. PMID: 35568678 No abstract available.

2

Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment.

Mathijssen RH, van Schaik RH. Mathijssen RH, et al. Eur J Cancer. 2006 Jan;42(2):141-8. doi: 10.1016/j.ejca.2005.08.035. Epub 2005 Dec 1. Eur J Cancer. 2006. PMID: 16325399 Review.

3

Medicinal cannabis in oncology.

Engels FK, de Jong FA, Mathijssen RH, Erkens JA, Herings RM, Verweij J. Engels FK, et al. Eur J Cancer. 2007 Dec;43(18):2638-44. doi: 10.1016/j.ejca.2007.09.010. Epub 2007 Oct 31. Eur J Cancer. 2007. PMID: 17976975 Review.

4

Lifestyle habits as a contributor to anti-cancer treatment failure.

de Jong FA, Sparreboom A, Verweij J, Mathijssen RH. de Jong FA, et al. Eur J Cancer. 2008 Feb;44(3):374-82. doi: 10.1016/j.ejca.2007.12.012. Epub 2008 Jan 22. Eur J Cancer. 2008. PMID: 18207386 Review.

5

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.

de Jonge MJ, Slingerland M, Loos WJ, Wiemer EA, Burger H, Mathijssen RH, Kroep JR, den Hollander MA, van der Biessen D, Lam MH, Verweij J, Gelderblom H. de Jonge MJ, et al. Eur J Cancer. 2010 Nov;46(16):3016-21. doi: 10.1016/j.ejca.2010.07.015. Epub 2010 Aug 26. Eur J Cancer. 2010. PMID: 20801016 Clinical Trial.

6

Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.

van der Bol JM, Loos WJ, de Jong FA, van Meerten E, Konings IR, Lam MH, de Bruijn P, Wiemer EA, Verweij J, Mathijssen RH. van der Bol JM, et al. Eur J Cancer. 2011 Apr;47(6):831-8. doi: 10.1016/j.ejca.2010.11.030. Epub 2011 Jan 6. Eur J Cancer. 2011. PMID: 21216137 Free article. Clinical Trial.

7

Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific binding.

de Bruijn P, de Graan AJ, Nieuweboer A, Mathijssen RH, Lam MH, de Wit R, Wiemer EA, Loos WJ. de Bruijn P, et al. J Pharm Biomed Anal. 2012 Feb 5;59:117-22. doi: 10.1016/j.jpba.2011.10.010. Epub 2011 Oct 24. J Pharm Biomed Anal. 2012. PMID: 22079047

8

Danusertib, an aurora kinase inhibitor.

Meulenbeld HJ, Mathijssen RH, Verweij J, de Wit R, de Jonge MJ. Meulenbeld HJ, et al. Expert Opin Investig Drugs. 2012 Mar;21(3):383-93. doi: 10.1517/13543784.2012.652303. Epub 2012 Jan 13. Expert Opin Investig Drugs. 2012. PMID: 22242557 Review.

9

The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin.

van Jaarsveld MT, Blijdorp IC, Boersma AW, Pothof J, Mathijssen RH, Verweij J, Wiemer EA. van Jaarsveld MT, et al. Eur J Cancer. 2013 Jan;49(2):345-51. doi: 10.1016/j.ejca.2012.08.024. Epub 2012 Oct 4. Eur J Cancer. 2013. PMID: 23041051

10

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM. van Soest RJ, et al. Eur J Cancer. 2013 Dec;49(18):3821-30. doi: 10.1016/j.ejca.2013.09.026. Epub 2013 Oct 24. Eur J Cancer. 2013. PMID: 24200698

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

400 results

Search Page